



US 20150315262A1

(19) **United States**

(12) **Patent Application Publication**
Beyaert et al.

(10) **Pub. No.: US 2015/0315262 A1**

(43) **Pub. Date: Nov. 5, 2015**

(54) **NOVEL INTERLEUKIN-33 INHIBITORS**

(30) **Foreign Application Priority Data**

(71) Applicants: **VIB VZW**, Gent (BE);
UNIVERSITEIT GENT, Gent (BE)

Dec. 10, 2012 (EP) 12196262.5

(72) Inventors: **Rudi Beyaert**, Zingem (BE); **Harald Braun**, Gent (BE); **Bart Lambrecht**, Laarne (BE); **Hamida Hammad**, Ronse (BE)

Publication Classification

(51) **Int. Cl.**
C07K 14/715 (2006.01)
(52) **U.S. Cl.**
CPC **C07K 14/7155** (2013.01); **C07K 2319/00** (2013.01); **A61K 38/00** (2013.01)

(21) Appl. No.: **14/649,526**

(57) **ABSTRACT**

(22) PCT Filed: **Dec. 10, 2013**

The present invention relates to novel inhibitors of IL-33. More specifically, it relates to a fusion protein of the soluble IL-33 receptor with the soluble IL-1RAcP as inhibitor of IL-33 activity. The invention relates further to the use of the inhibitor in treatment of IL-33-related diseases such as, but not limited to, asthma, atopic dermatitis and psoriasis.

(86) PCT No.: **PCT/EP2013/076082**

§ 371 (c)(1),

(2) Date: **Jun. 3, 2015**